Bottom line
XLV vs RYHIX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 79% by weight.
But RYHIX is far broader, holding 135 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
XLV is cheaper at 0.08% vs 1.38% — a difference of $130 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +5.1% for RYHIX.
Updated Nov 19, 2026
XLV vs RYHIX side by side
| XLV | RYHIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 1.38% |
| Annual cost per $10k | $8 | $138 |
| 10-yr cost on $10k (prospectus) | $103 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +14.4% |
| 5-yr return (annualized) | +8.1% | +5.1% |
| 10-yr return (annualized) | +9.8% | +7.9% |
| Best quarter | +14.5% | +18.7% |
| Worst quarter | −12.7% | −14.4% |
| Net assets (fund) | $40.6B | $19.4M |
| Number of holdings | 65 | 135 |
| Portfolio turnover | 2% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | RYHIX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +14.4% | +0.1% |
| 2024 | +2.5% | +0.6% | +1.9% |
| 2023 | +2.0% | +5.8% | −3.9% |
| 2022 | −2.1% | −11.6% | +9.6% |
| 2021 | +25.9% | +19.2% | +6.7% |
| 2020 | +13.3% | +18.9% | −5.7% |
| 2019 | +20.7% | +22.8% | −2.1% |
| 2018 | +6.3% | +1.6% | +4.7% |
| 2017 | +21.7% | +23.5% | −1.8% |
| 2016 | −2.8% | −9.4% | +6.5% |
Source: Fund prospectus bar charts
Holdings overlap
23 of XLV's top 25 holdings also appear in RYHIX's top 25.
| Holding | XLV | RYHIX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 3.63% |
| Johnson & Johnson | 10.64% | 2.88% |
| AbbVie Inc | 7.74% | 2.52% |
| UnitedHealth Group Inc | 6.57% | 2.22% |
| Merck & Co Inc | 5.52% | 2.04% |
| Amgen Inc | 3.40% | 1.56% |
| Thermo Fisher Scientific Inc | 3.24% | 1.61% |
| Abbott Laboratories | 2.75% | 1.42% |
| Gilead Sciences Inc | 2.73% | 1.39% |
| Intuitive Surgical Inc | 2.45% | 1.31% |
| Pfizer Inc | 2.39% | 1.25% |
| CVS Health Corp | 2.30% | 1.31% |
| Vertex Pharmaceuticals Inc | 2.19% | 1.34% |
| Danaher Corp | 2.09% | 1.30% |
| Bristol-Myers Squibb Co | 2.05% | 1.22% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between XLV and RYHIX?
Which is cheaper, XLV or RYHIX?
Should I own both XLV and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.